MSD to acquire Idenix
9 June 2014 | By Merck
MSD and Idenix Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which MSD will acquire Idenix for $24.50 per share in cash...
List view / Grid view
News
First patient enrolled in new Phase 3 trial program investigating a once-daily dosing regimen of ISENTRESS® (raltegravir)
6 June 2014 | By Merck
MSD announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK...
GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome
6 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the start of a pivotal phase III study, LATITUDE-TIMI 60, to evaluate the effects of losmapimod in patients presenting with acute coronary syndrome...
Pivotal Phase III data show polycythemia vera patients on Novartis drug Jakavi® achieved significant improvement in disease control
5 June 2014 | By Novartis
Novartis announced results from the first-ever pivotal Phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera (PV)...
Teva to acquire Labrys Biologics, Inc.: Novel migraine prophylaxis treatment adds significant new dimension to Teva’s growing pain care franchise
4 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities...
One- & two-year survival rates of 94% and 88% announced from Phase 1b trial of investigational PD-1 checkpoint inhibitor nivolumab and yervoy® (ipilimumab) in advanced melanoma
3 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced follow up results from Study -004, a multi-arm Phase 1b dose-ranging trial evaluating the safety and activity of the combination regimen of nivolumab...
Roche acquires Genia Technologies to strengthen next generation sequencing pipeline
2 June 2014 | By Roche
Roche announced the acquisition of Genia Technologies, Inc., a privately held company, based in Mountain View, California, USA...
GSK announces Phase III ALTTO results for anti-HER2 therapy combination in the adjuvant breast cancer treatment setting
2 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival...
Leading experts from pharma and biotech companies to meet in London in September at Biosimilars and Biobetters Conference
29 May 2014 | By SMI Group
Impending patent expirations on blockbuster biologics and a volatile financial environment is causing payers to seek wider adoption of biosimilars in order to manage growing healthcare costs...
Bionetworks: reviewing the various collaborations between pharma, biotech, academia and venture capitalists
29 May 2014 | By SMI Group
Companies are realizing that their own internal R&D groups alone are not enough and as pharma groups slash their internal R&D projects...
George Weinstock to Keynote at Next Generation Seq Meeting on June 19-20, 2014 in San Diego, CA
29 May 2014 | By GTCBio
George Weinstock, Professor and Associate Director at The Jackson Laboratory for Genomic Medicine to give a keynote presentation on “Exploring the Role of the Microbiome in Disease”...
John Herrmann, CSO, Eli Lilly to Keynote at Novel Cancer Therapeutics Summit – July 7-8, 2014 Boston
29 May 2014 | By GTCBio
John Herrmann, Chief Science Officer of Global External Research & Development, Oncology at Eli Lilly To Give a Keynote Presentation on “Partnering with Lilly Oncology: Current Priorities, NYC Innovation Hub Model & Possible Future States” at the Novel Cancer Therapeutics Summit 2014...
Dainippon Sumitomo Pharma and Daiichi Sankyo cooperate on lurasidone, an atypical antipsychotic agent, in four South American countries
27 May 2014 | By Daiichi Sankyo
Dainippon Sumitomo Pharma Co., Ltd. and Daiichi Sankyo Co., Ltd. announced that they have entered into a license agreement for the commercialization of lurasidone hydrochloride...
Pfizer announces detailed results for Phase 3 OPT retreatment study of tofacitinib in adults with moderate-to-severe chronic plaque psoriasis
23 May 2014 | By Pfizer
Pfizer Inc. announced detailed results from the Oral treatment Psoriasis Trial Retreatment study, a Phase 3 study investigating tofacitinib for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis...
Sanford-Burnham and Daiichi Sankyo form alliance to study novel drug targets in cardiovascular-metabolic diseases
22 May 2014 | By Daiichi Sankyo
Sanford-Burnham Medical Research Institute and Daiichi Sankyo Co., Ltd. announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases...
